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This issue of Therapeutics and Clinical Risk Management contains several excellent 
review articles which focus on diverse disorders. Nonsmall cell lung cancer 
(NSCLC) is the most common form of the malignancy accounting for 80% of 
cases. For the most part these patients present with advanced disease for which 
tumor resection is not an option. Treatment of advanced disease is therefore aimed 
at improving survival rates. It is important therefore that the associated side effects 
of treatment do not impact too heavily on the quality of life of patients. Therapy for 
NSCLC involves chemotherapy with cisplatin or carboplatin in combination with a 
third-generation cytotoxic drug: vinorelbine, gemcitabine, paclitaxel, or docetaxel. 
Felip and Rosell (2008) provide a comprehensive review of the clinical utility and 
toxicity proﬁ  le of pemetrexed, a multi-targeted antifolate agent, in the treatment of 
NSCLC. Until recently, docetaxel was the only approved cytotoxic chemotherapy 
for second-line NSCLC treatment. The authors ﬁ  rst reviewed the effectiveness of 
pemetrexed as a second-line treatment for advanced NSCLC. They concluded that 
when administered with folic acid and vitamin B12, pemetrexed had comparable 
efﬁ  cacy and a superior toxicity proﬁ  le relative to docetaxel. They also addressed 
the use of pemetrexed in combination with cisplatin as a ﬁ  rst line treatment for 
NSCLC and report equivalent responses and overall patient survival compared 
to a combination of cisplatin with gemcitabine. The authors also addressed the 
potential role of targeted agents in combination with pemetrexed together with 
the use of pharmacogenomic approaches to predict chemotherapeutic responses 
in NSCLC patients.
Chronic infection with hepatitis C virus is the major cause of liver cirrhosis 
and carcinoma and is responsible for approximately half of the indications for liver 
transplantation worldwide. Liver transplantation represents an effective treatment 
option but graft re-infection is virtually inevitable in those patients with detect-
able serum hepatitis C virus RNA at the time of transplant. In a very interesting 
review, Toniutto and colleagues (2008) consider the effectiveness of antiviral 
treatment of hepatitis C-positive patients awaiting liver transplant. Interferon 
in combination with ribavirin represent the mainstay treatments and in addition 
to improving graft survival; antiviral treatment may remove the need for a liver 
transplant thereby saving scarce donated organs. Although this approach appears 
effective, the authors recommend caution as results obtained to date are from 
small and uncontrolled clinical studies of less than 300 patients with a relative 
short period of follow-up. They conclude by stating that in those transplant centres 
where the time of the operation can be predicted with some degree of accuracy, 
limited antiviral regimens including novel drugs might prove to be effective in 
hepatitis C virus-infected patients.
Neff and colleagues (2008) review treatment options for mucous membrane pem-
phigoid (MMP). This is an autoimmune blistering disorder of mucous membranes 
characterized by subepithelial bullae involving the oral cavity, conjunctiva, nasophar-
ynx, larynx, esophagus, genitourinary tract, and anus. Skin involvement is observed in 
approximately one-quarter of patients and is usually limited to the head, neck and upper 
torso. MMP presents with a spectrum of symptoms; the authors describe diagnostic 
criteria and clinical features and how these inform the various treatment options for this 
condition. Three monoclonal tumour necrosis factor-α (TNF-α) inhibitors are currently Therapeutics and Clinical Risk Management 2008:4(3) ii
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available: etanercept, inﬂ  iximab, and adalimumab. All have 
efﬁ  cacy in the treatment of rheumatoid arthritis and with a 
more variable response in other granulomatous diseases such 
as sarcoidosis, Crohn’s disease or Wegener’s granulomatosis. 
It is of interest therefore that anti-TNF-α agents also appear 
effective in MMP that is refractive to treatment with more 
established therapies. The authors conclude by pointing out 
that as MMP is a relatively rare disorder there is a lack of 
well-conducted, large, randomized controlled trials com-
paring the efﬁ  cacy of various therapeutic agents and that a 
multidisciplinary approach is recommended for identifying 
the appropriate therapy for each individual patient.
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